US House sends drug bill to Senate for final vote

June 20, 2012

(AP) — The House on Wednesday passed a major bill affecting the Food and Drug Administration that will increase inspections of drug manufacturing facilities overseas, while also funding review of new drugs at home.

Under the , approved by majority voice vote Wednesday, the FDA will have more flexibility to inspect sites in China, India and other countries. The number of U.S. drugs produced overseas has more than doubled over the last decade.

The underlying legislation renews an agreement under which companies pay the FDA to review new products. The FDA will collect $6.4 billion in fees from companies over the next five years. For the first time, the agency will collect fees from generic drugmakers to speed up approvals of their therapies. The FDA currently has a backlog of roughly 2,700 generic drugs awaiting review.

Other sections of the bill increase fines for drug counterfeiting and require drugmakers to notify the government earlier of potential drug shortages. More than 280 drugs are currently in short supply in the U.S., due in part to drug industry consolidation.

The bill sorts out differences in prior legislation passed by the House and Senate. House lawmakers approved their initial version of the sweeping legislation last month in a 387-5 vote.

The Senate is expected to vote on the bill next week, after which it will go to White House to be signed into law.

Explore further: New US legislation aims to curb cancer drug shortages (Update)

shares

Related Stories

New US legislation aims to curb cancer drug shortages (Update)

June 4, 2012
A critical shortage of generic drugs in the United States, particularly in cancer care, could be curbed with legislation now being hammered out by the US House and Senate, doctors said on Monday.

US lawmakers reject Canada drug purchases

October 20, 2011
The US Senate Thursday rejected a measure that would have enabled Americans to buy prescription drugs in Canada in a bid to reduce the costs of their health care.

Recommended for you

Glucocorticoids offer long-term benefits for patients with Duchenne muscular dystrophy

November 22, 2017
Glucocorticoids, a class of steroid hormone medications often prescribed to patients with Duchenne muscular dystrophy (DMD), offer long-term benefits for this disease, including longer preservation of muscle strength and ...

Baby-boomers and millennials more afflicted by the opioid epidemic

November 21, 2017
Baby-boomers, those born between 1947 and 1964, experienced an excess risk of prescription opioid overdose death and heroin overdose death, according to latest research at Columbia University's Mailman School of Public Health. ...

Sensor-equipped pill raises technological, ethical questions

November 17, 2017
The first drug with a sensor embedded in a pill that alerts doctors when patients have taken their medications was approved by the Food and Drug Administration, raiding issues involving privacy, cost, and whether patients ...

New painkillers reduce overdose risk

November 16, 2017
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have developed new opioid pain relievers that reduce pain on par with morphine but do not slow or stop breathing—the cause of opiate overdose.

Separating side effects could hold key for safer opioids

November 16, 2017
Opioid pain relievers can be extremely effective in relieving pain, but can carry a high risk of addiction and ultimately overdose when breathing is suppressed and stops. Scientists have discovered a way to separate these ...

US regulators approve first digital pill to track patients

November 14, 2017
U.S. regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.